ViewRay® Appoints Brian K. Roberts to its Board of Directors

CLEVELAND, Dec. 29, 2015 /PRNewswire/ -- ViewRay, Inc. (OTCQB: VRAY) announced today the appointment of Brian K. Roberts to the company's Board of Directors. Roberts will also serve as the Chair of the Audit Committee.

"We are delighted to have Brian join our Board of Directors and assume the position of Audit Committee Chair," said Chris A. Raanes, President and Chief Executive Officer of ViewRay. "Brian's expertise in medical technology and his extensive experience as a CFO in both public and private companies make him a valuable addition to our Board."

"I'm pleased to join the ViewRay Board of Directors at such an exciting time in the company's development," said Roberts. "I look forward to helping ViewRay build on its recent successes and bring the benefits of the MRIdian system, the world's first and only MRI-guided radiation therapy system, to cancer patients all around the world."

Roberts currently serves as the Chief Operating and Financial Officer of Avedro, the leader in corneal cross-linking science, which recently completed a $32 million equity financing. Prior to Avedro, Roberts served as CFO for Insulet Corporation. During his time at Insulet, the tubeless insulin pump technology company grew from approximately $30 million to nearly $300 million in revenue, achieved operating profitability, and increased its market capitalization to over $2 billion.

Previously, Roberts served as CFO for Jingle Networks, a leader in mobile voice-ad services that was acquired by Marchex, Inc., and as CFO for Digitas, which was sold for $1.3 billion to Publicis Groupe. He holds a Bachelor of Science in Accounting and Finance from Boston College, is a Certified Public Accountant, and served as an auditor with Ernst & Young LLP.

About ViewRay

ViewRay, Inc. of Cleveland, Ohio, is a medical device company that develops advanced radiation therapy technology for the treatment of cancer. The MRIdian^® system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy.

ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

SOURCE ViewRay, Inc.